The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 02, 2016

Filed:

Aug. 26, 2014
Applicant:

Amicus Therapeutics, Inc., Cranbury, NJ (US);

Inventor:

Brandon Alan Wustman, San Diego, CA (US);

Assignee:

Amicus Therapeutics, Inc., Cranbury, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/445 (2006.01); A61K 31/437 (2006.01); A61K 31/45 (2006.01); A61K 31/194 (2006.01); A61K 31/713 (2006.01);
U.S. Cl.
CPC ...
A61K 31/445 (2013.01); A61K 31/194 (2013.01); A61K 31/437 (2013.01); A61K 31/45 (2013.01); A61K 31/713 (2013.01); A61K 2300/00 (2013.01);
Abstract

Provided is a method of increasing the stability of wild-type β-glucocerebrosidase. Also provided are methods of treating and/or preventing an individual having a neurological disease in which increased expression or activity of β-glucocerebrosidase in the central nervous system would be beneficial. This method comprises administering an effective amount of a pharmacologic chaperone for β-glucocerebrosidase, with the proviso that the individual does not have a mutation in the gene encoding β-glucocerebrosidase. Further provided are β-glucocerebrosidase inhibitors which have been identified as specific pharmacologic chaperones and which have been shown to increase activity of β-glucocerebrosidase in vivo in the central nervous system.


Find Patent Forward Citations

Loading…